Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IAP086 in Persons With HIV-1 on Antiretroviral Therapy
NCT07596888Phase 1Recruiting
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Jun 2026
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of IAP086 in human immunodeficiency virus infection (HIV) (9 cohorts), sponsored by University of North Carolina at Chapel Hill. Primary endpoints: Number of Serious Adverse Events at 28 days, Number of Grade 3 or Greater (Severe) Adverse Events at 28 days and 2 more. Started Jun 2026; status: recruiting.
02
Drugs
IAP086
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07596888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07596888.